These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1052 related items for PubMed ID: 17509298

  • 1. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS, Pacificar JS, Shapiro CE, Williams SG.
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [Abstract] [Full Text] [Related]

  • 2. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
    Greil S, Robinson EA, Singal B, Kleer E.
    Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301
    [Abstract] [Full Text] [Related]

  • 3. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T, Nishizawa K, Mitsumori K.
    Scand J Urol Nephrol; 2006 Mar; 40(3):198-203. PubMed ID: 16809259
    [Abstract] [Full Text] [Related]

  • 4. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.
    Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC.
    J Urol; 2000 Dec; 164(6):1891-4. PubMed ID: 11061874
    [Abstract] [Full Text] [Related]

  • 5. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW, Clarke HS, Hancock WC, Keane TE.
    Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
    [Abstract] [Full Text] [Related]

  • 6. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I.
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S, Lawrentschuk N, Grills RJ, Neerhut G.
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 10. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
    Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS.
    J Urol; 2006 Feb 15; 175(2):533-6. PubMed ID: 16406989
    [Abstract] [Full Text] [Related]

  • 11. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

  • 12. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
    Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R.
    J Urol; 2008 Oct 01; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
    [Abstract] [Full Text] [Related]

  • 13. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB, Mottet N.
    BJU Int; 2012 Aug 01; 110(4):499-504. PubMed ID: 22093775
    [Abstract] [Full Text] [Related]

  • 14. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T, Nasu Y, Kumon H.
    Prostate; 2006 Mar 01; 66(4):439-44. PubMed ID: 16329145
    [Abstract] [Full Text] [Related]

  • 15. Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.
    van der Sluis TM, van Moorselaar RJ, Meuleman EJ, ter Haar RW, Bui HN, Heijboer AC, Vis AN.
    Urology; 2013 May 01; 81(5):1005-9. PubMed ID: 23465153
    [Abstract] [Full Text] [Related]

  • 16. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
    Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK, Degarelix Study Group.
    J Urol; 2008 Nov 01; 180(5):1986-92. PubMed ID: 18801505
    [Abstract] [Full Text] [Related]

  • 17. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M.
    Clin Ther; 2009 Nov 01; 31 Pt 2():2312-31. PubMed ID: 20110043
    [Abstract] [Full Text] [Related]

  • 18. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J.
    Urol Int; 2006 Nov 01; 77(2):135-8. PubMed ID: 16888418
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug 01; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.